Padley David, Ferguson Morag, Warwick Ruth M, Womack Christopher, Lucas Sebastian B, Saldanha John
Division of Virology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Herts EN6 3QG, UK.
Cell Tissue Bank. 2005;6(3):171-9. doi: 10.1007/s10561-005-5421-9.
Natural changes that occur in blood and tissue after death may result in false positive results in antigen and antibody detection tests performed to identify markers of viral infection in potential tissue donors. Such tissue, which might otherwise be acceptable for therapeutic purposes, would not meet current standards for safe tissue banking. This is especially important in the context of insufficiency in the tissue supply. In this study, a series of blood samples collected during routine post-mortem examination was assayed using a range of commercially available kits for the detection of HBsAg, anti-HCV and anti-HIV 1 + 2 antibody/antigen. Results of tests on 104 samples collected from 97 individuals indicate that some kits result in a higher number of initial reactive samples than others. Approximately 40% of samples were reactive in one or more HBsAg assay, less than 10% in at least one anti-HIV kit and only 1 sample at low level on an anti-HCV kit. Liver or lymph node samples from individuals whose serum sample gave reactive results in antigen/antibody assays were tested for viral nucleic acid in the corresponding nucleic acid amplification test. Only one individual's sample was confirmed to test positive for HBsAg in a confirmatory neutralisation test and by nucleic acid amplification technology, and a second individual whose serum was scored reactive for anti-HCV, but negative for HBsAg, had a liver sample which was HBV DNA positive and HCV RNA negative. The results of the study indicate that antibody/antigen assays are not as specific as NAT using state of the art DNA extraction techniques. Both types of assay complement each other and used together will help assure the safety of tissues for transplantation.
死后血液和组织中发生的自然变化可能会导致在对潜在组织供体进行病毒感染标志物检测的抗原和抗体检测试验中出现假阳性结果。这样的组织,若用于治疗目的原本可能是可接受的,但不符合当前安全组织库的标准。在组织供应不足的情况下,这一点尤为重要。在本研究中,使用一系列市售试剂盒对常规尸检期间采集的一系列血样进行检测,以检测乙肝表面抗原(HBsAg)、抗丙型肝炎病毒(抗-HCV)以及抗人类免疫缺陷病毒1 + 2抗体/抗原。从97名个体采集的104份样本的检测结果表明,某些试剂盒产生的初始反应性样本数量比其他试剂盒更多。约40%的样本在一种或多种HBsAg检测中呈反应性,在至少一种抗-HIV试剂盒中反应性低于10%,而在一种抗-HCV试剂盒中只有1份样本呈低水平反应性。对血清样本在抗原/抗体检测中呈反应性的个体的肝脏或淋巴结样本进行相应核酸扩增试验中的病毒核酸检测。在确证中和试验及核酸扩增技术检测中,仅1名个体的样本被确认为HBsAg检测呈阳性,另1名个体血清抗-HCV检测呈反应性但HBsAg检测呈阴性,其肝脏样本HBV DNA呈阳性而HCV RNA呈阴性。研究结果表明,使用先进DNA提取技术时,抗体/抗原检测不如核酸扩增检测(NAT)特异。两种检测方法相互补充,联合使用将有助于确保移植组织的安全性。